EMBER-3 Trial Results
December 8, 2025 • ESR1 Mutated ER HER2 Advanced Breast Cancer Content Hub
In this video, Virginia Kaklamani, MD, UT Health San Antonio, Texas, reviews the results of the EMBER-3 Phase 3 trial of imlunestrant, an oral SERD, in patients with ER+, HER2- advanced breast cancer. The results show that, in patients with ESR1 mutations, imlunestrant alone significantly lengthened progression-free survival compared with standard hormone therapy, and when combined with abemaciclib, further increased PFS across all patients. The combination therapy also produced higher response rates and had an acceptable safety profile compared with monotherapy or standard care.
